Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPC | P11150 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 3/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17018106 | 0.87 | BRD4 (0.51) | LIPCBRD4S1PR1PIK3CALIPG | |
| SCHEMBL17018099 | 0.87 | BRD4 (0.56) | LIPCBRD4S1PR1PIK3CALIPG | |
| SCHEMBL17018114 | 0.86 | BRD4 (0.47) | LIPCBRD4S1PR1PIK3CALIPG | |
| SCHEMBL21249889 | 0.85 | BRD4 (0.40) | LIPCBRD4PIK3CALIPGTBK1 | |
| SCHEMBL17018232 | 0.80 | BRD4 (0.56) | BRD4PIK3CA | |
| SCHEMBL17018243 | 0.80 | BRD4 (0.51) | BRD4PIK3CATBK1FGFR1 | |
| SCHEMBL17018269 | 0.80 | BRD4 (0.47) | LIPCBRD4PIK3CALIPGFGFR1 | |
| SCHEMBL17018102 | 0.79 | BRD4 (0.61) | BRD4PIK3CAFGFR1 | |
| SCHEMBL17018120 | 0.78 | BRD4 (0.51) | BRD4PIK3CAGSK3BDYRK1ATBK1 | |
| SCHEMBL17018110 | 0.78 | BRD4 (0.55) | BRD4PIK3CAGSK3BDYRK1ATBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084831-B1 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084831-B1 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | LIPC 870/4885BRD4 1/4885S1PR1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.